Table 1.

Trials exploring ACE inhibitor dosing regimens in heart failure

Trial	ACE-I regimens (daily doses)	Major findings
NETWORK (n = 1532)	Enalapril 2.5 mg bid vs 5 mg bid vs 10 mg bid	No difference in hospitalizations for heart failure; trend
	Follow-up: 5.5 months	towards fewer deaths with increasing dose
ATLAS (n = 3164)	Lisinopril 2.5-5 mg od vs 32.5-35 mg od	Trends towards reduced total and CV mortality and
	Follow-up:46 months	significant reduction in mortality and all-cause
		hospitalizations for high-dose lisinopril
CHIPS (n = 298)	Captopril 25 mg bid vs 50 mg bid	Trend towards reduced hospitalizations for heart failure and
	Follow-up: 2 years	towards reduced fatal and nonfatal cardiac events for
		high-dose captopril
HEDS (n = 248)	Enalapril 20 mg vs 60 mg	No significant differences in survival, clinical and
	Follow-up: 12 months	hemodynamic variables

ACE-I = angiotensin-converting enzyme inhibitor; ATLAS = Assessment of Treatment with Lisinopril and Survival; CHIPS = Captopril in Heat Insufficient Patients Study; HEDS = High Enalapril Dose Study; NETWORK = Network of General Practitioners and Hospital Physicians Involved in the Study of Low versus High Doses of Enalapril in Patients with Heart Failure trial.